Abstract

Dyslipidemia is a risk factor for metabolic syndrome. The aim of the study: evaluation of dyslipidemia as the risk factor in people with and without metabolic syndrome.

Materials and methods

The study involved 401 healthy individuals aged 25-55 years old. There were chosen at random in Tirana it included generalities, sex, residence, age, weight, abdominal circumference, systolic blood pressure, diastolic blood pressure, pulse, BMI, cholesterol, triglyceride, LDL, HDL, glicemia, insulinenia, HOMA - R. Insulin resistance and insulin sensitivity were calculated and compared within people with and without MS. MS prevalence was determined by IDF criteria.

Results

It was noticed that there is a significant link between triglyceride in persons with MS and those without MS (P< 0.001). There was also an important link between HDL in persons with MS and those without MS (P< 0.001). It is noticed an important connection between pulse pressure and total cholesterol (P = 0.02) (r = -0.130). There was also between pulse pressure and triglyceride ((P=0.002), (r=0.158). In people with MS was a significant correlation between triglyceride and glicemia (P = 0.022), (r = 0.253). There was also an important link between triglyceride and insulineni (P = 0.0002), (r = 0.403). In this people was a significant correlation between triglyceride and HOMA - IR (P = 0.001), (r = 0.489). There was also an important link between triglyceride and insulin sensitivity ((P = 0.003), (r = 0.326).

Keywords

MS - metabolic syndrome
IDF - International Diabetes Federation

Background

This dyslipidemia is characterised by a spectrum of qualitative lipid abnormalities reflecting perturbations in the structure, metabolism, and biological activities of both atherogenic lipoproteins and antiatherogenic HDL-C which includes an elevation of lipoproteins containing apolipoprotein B (apoB), elevated TGs, increased levels of small particles of LDL, and low levels of HDL-C. Insulin resistance leads to an atherogenic dyslipidemia in several ways. First, insulin normally suppresses lipolysis in adipocytes, so an impaired insulin signalling increases lipolysis, resulting in increased FFA levels. In the liver, FFAs serve as a substrate for the synthesis of TGs. FFAs also stabilize the production of apoB, the major lipoprotein of very low density lipoprotein (VLDL) particles, resulting in a more VLDL production. Second, insulin normally degrades apoB through PI3K-dependent pathways, so an insulin resistance directly increases VLDL production. Third, insulin regulates the activity of lipoprotein lipase, the rate-limiting and major mediator of VLDL clearance. Thus, hypertriglyceridemia in insulin resistance is the result of both an increase in VLDL production and a decrease in VLDL clearance. VLDL is metabolized to remnant lipoproteins and small dense LDL, both of which can promote an atheroma formation. The TGs in VLDL are transferred to HDL by the cholesterol ester transport protein (CETP) in exchange for cholesteryl esters, resulting in the TG-enriched HDL and cholesteryl ester-enriched VLDL particles. Further, the TG-enriched HDL is a better substrate for hepatic lipase, so it is cleared rapidly from the circulation, leaving a few HDL particles to participate in a reverse cholesterol transport from the vasculature. Thus, in the liver of insulin-resistant patients, FFA flux is high, TGs synthesis and storage are increased, and excess TG is secreted as VLDL [1]. For the most part, it is believed that the dyslipidemia associated with insulin resistance is a direct consequence of increased VLDL secretion by the liver [2]. These anomalies are closely associated with an increased oxidative stress and an endothelial dysfunction, thereby reinforcing the proinflammatory nature of macrovascular atherosclerotic disease.
Worldwide prevalence of MetS ranges from <10% to as much as 84%, depending on the region, urban or rural environment, composition (sex, age, race, and ethnicity) of the population studied, and the definition of the syndrome used [4, 5]. In general, the IDF estimates that one-quarter of the world’s adult population has the MetS [9]. Higher socioeconomic status, sedentary lifestyle, and high body mass index (BMI) were significantly associated with MetS. Cameron et al. have concluded that the differences in genetic background, diet, levels of physical activity, smoking, family history of diabetes, and education all influence the prevalence of the MetS and its components [6]. The observed prevalence of the MetS in National Health and Nutrition Examination Survey (NHANES) was 5% among the subjects of normal weight, 22% among the overweight, and 60% among the obese [7]. It further increases with age (10% in individuals aged 20–29, 20% in individuals aged 40–49, and 45% in individuals aged 60–69) [8]. The prevalence of MetS (based on NCEP-ATP III criteria, 2001) varied from 8% to 43% in men and from 7% to 56% in women around the world [6]. Park et al. [7] noticed that there is an increase in the prevalence of MetS from 20 years old through the sixth and seventh decade of life for males and females, respectively.

The aim of the study

Evaluation of dyslipidemia as the risk factor in people with and without metabolic syndrome.

Materials and methods

The study involved 401 healthy individuals aged 25-55 years old. There were chosen at random in Tirana it included generalities, sex, residence, age, weight, abdominal circumference, systolic blood pressure, diastolic blood pressure, pulse, BMI, cholesterol, triglyceride, LDL, HDL, glycemia, insulinemia, HOMA –R. Insulin resistance and insulin sensitivity were calculated and compared within people with and without MS. MS prevalence was determined by IDF criteria.

Statistical analysis

Continuous data were presented in the average value and standard deviation.

The relationships between variables were studied with the Pearson correlation.

Discrete data presented in absolute value and percentage.

Differences between the two groups for continuous quantitative variables was performed through student test.

Data analysis was performed with SPSS statistical package, version 20, (Statistical Package for Social Sciences).

The level of significance was accepted at P < 0.05

Results

The study involved 401 healthy individuals (166 men and 235 women (41.4% males and 58.6% females). The study involved 401 healthy individuals aged 25-55 years old. There were chosen at random in Tirana.

Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>N</th>
<th>Average</th>
<th>SD</th>
<th>t</th>
<th>Df</th>
<th>Sig. (2-tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG yes</td>
<td>83</td>
<td>183.80</td>
<td>138.25</td>
<td>8.3</td>
<td>39</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TG no</td>
<td>31</td>
<td>105.56</td>
<td>48.4</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL yes</td>
<td>83</td>
<td>39.37</td>
<td>5.01</td>
<td>-4.4</td>
<td>39</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL no</td>
<td>31</td>
<td>43.37</td>
<td>7.70</td>
<td>-</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>LD yes</td>
<td>83</td>
<td>116.95</td>
<td>31.0</td>
<td>-</td>
<td>39</td>
<td>0.521</td>
</tr>
<tr>
<td>LD no</td>
<td>31</td>
<td>136.50</td>
<td>44.8</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

It was noticed that there is a significant link between triglyceride in persons with MS and those without MS (P < 0.001).
There was also an important link between triglyceride and insulinemia (P = 0.0002), (r = 0.403)
In this people was a significant correlation between triglyceride and HOMA-IR (P = 0.001), (r = 0.489)
There was also an important link between triglyceride and insulin sensitivity ((P = 0.003), (r = 0.326).

Conclusions

As a result of our study, it was noticed that hypertriglyceridemia that was present in persons with MS, associated with low HDL has a major effect in insulin resistance and endothelial dysfunction. High levels of cholesterol had also an effect in endothelial dysfunction.

References


Biography

VIOLETA HOXHA received the B.S. degree in Medicine from the Medical University of Tirana, Albania, in 1994, specialized in Endocrinology from the Medical University of Tirana, Albania in 2001, earned a Master Degree in 2008 from Medical University of Tirana, Albania, and is doctorate in process. Currently, she is working as an endocrinologist in “Mother Theresa” Hospital, and teaching First aid and Medical emergencies to medical students in Medical University of Tirana, Albania. She has authored and co-authored 56 other research articles and a European project about the genetics of metabolic syndrome in 2015. Violeta Hoxha may be reached at hoxha_violeta@yahoo.com